Pro: Can neuropathology really confirm the exact diagnosis? by Esiri, Margaret M
Th   ere was a time (up to the 1960s and 1970s) when few 
would have questioned that a neuropathological exami-
nation of the brain at autopsy was needed to make a 
diagnosis of Alzheimer’s disease (AD). Th   is was at a time 
when clinical diagnostic instruments and neuroimaging 
were in their infancy. It was also a time when dementia 
was clinically divided into pre-senile and senile forms 
and the AD pathological label was applied most conﬁ  -
dently in pre-senile cases. Much has changed since then, 
and it is appropriate to ask whether neuropathology is 
still the gold standard by which to reach such a diagnosis.
Many cases of clinical AD are correctly diagnosed in life 
if the person concerned is seen by a specialist with much 
experience of the condition. Th  e proportion of cases 
correctly diagnosed will continue to climb if specialists 
have access to advancing imaging and other diagnostic 
procedures. Th   e situation is diﬀ  erent, however, if the diag-
nosis is made by someone without specialised knowledge 
or without access to state-of-the-art investigations.
Even among cases seen by specialists there will be a few 
that defy a correct diagnosis either because they present 
atypically or because a rare disease is masquerading as 
clinical AD. I have seen both. Frontotemporal dementia 
and AD can sometimes be indistinguishable until micro-
scopic sections have been examined. Th   ese cases cannot 
be correctly diagnosed without recourse to the micro-
scope, and even then may fail to ﬁ   t criteria for a 
diagnostic label. Only through the careful pathological 
assessment of such cases, however, often assisted by new 
pathological techniques (for example, new antibodies, 
genetic probes), will progress in delineating new or newly 
recognised diseases evolve.
Although it may at present only be in the minority of 
cases that neuropathology is required to attach the 
correct diagnosis to a case of dementia, it can be diﬃ   cult 
to predict in life which cases will fall into this category. 
Furthermore, diseases change and evolve over time. One 
hundred years ago it was possible to clinically confuse 
AD with tertiary syphilis but pathology provided a ready 
distinction. Now it is more likely that confusion might 
arise with respect to AD and AIDS-related dementia. 
Where will the confusion come from in the future? We 
need to remain watchful for novel forms of disease 
arising, and we need look no further than new variant 
Creutzfeldt–Jakob disease to be reminded of this.
Aﬃ   xing a single, speciﬁ  c diagnostic label, whether at 
the clinical or pathological level, is generally more easily 
achieved in young patients in whom the brain succumbs 
to a single pathological process. Th  e  diﬃ   culty with AD is 
that it is a condition whose incidence rises exponentially 
with age [1] when multiple factors may contribute to 
cognitive decline. Th  ese are likely to be diﬀ  erent  in 
diﬀ   erent individuals and not all of them can yet be 
apportioned their real share of blame. Hence, unitary 
diagnoses are much less likely to apply. It was through 
pathological studies that we were made aware of how 
much cerebrovascular disease, particularly small vessel 
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Recent advances in the clinical diagnostic instruments 
for diagnosing Alzheimer’s disease (AD) and in 
neuroimaging may cast doubt in the minds of 
some practitioners about the continued need for 
neuropathology to provide the ultimate diagnosis. 
Certainly the majority of cases of AD can be clinically 
correctly diagnosed by experienced clinicians but 
many cases are given this label by less experienced 
practitioners. Even after the most thorough work-up, 
a few cases of confi  dently diagnosed AD turn out to 
be something else when microscopy of the brain is 
undertaken. Even for neuropathologists, however, it 
can be diffi   cult to correctly assign cognitive decline 
to the various pathological processes that can be 
found together in an older brain. We need further 
clinicopathogical study to enlighten us about, for 
example, the contribution of commonly found 
cerebrovascular disease to dementia. Human studies 
are also needed to explore the changes in pathology 
that new treatments for AD may produce.
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vascular disease can now be assessed quite well with 
neuroimaging, but we still lack thorough understanding 
of exactly what contribution cerebrovascular disease 
makes to cognitive impairment [3].
We still need well-designed clinicopathological studies 
to acquire a much better understanding of the complexi-
ties of the pathological basis of cognitive decline in the 
older person and the many factors that feed into the 
clinical expression of pathological disease. Pathological 
examination of the brain provides a much more secure 
foundation on which to base understanding of the 
cellular and molecular changes that contribute to demen-
tia, including AD, than do clinical and imaging data. 
Community-based studies have shown us how misleading 
can be the impression of rather stereotyped disease that 
is gained from case–control cohorts. Unbiased (blind to 
cognitive function) pathological assessment of brains 
from a random community sample of older subjects – 
such as is provided in the UK by the Medical Research 
Council Cognitive Function and Ageing Study (www.cfas.
ac.uk) – enable us to appreciate how variable is clinical 
expression of AD pathology [4-6]. Such studies indicate 
the need to uncover the factors that enable someone with 
well-developed pathological features of AD to perform 
perfectly well in activities of daily life. Such knowledge 
will be essential given the massive rise in the world’s 
older population.
Until we have reliable biomarkers that enable a conﬁ  -
dent diagnosis of AD to be made in life, which reﬂ  ects the 
pathological basis of this disease, an autopsy examination 
of the brain remains an essential tool. With all due 
respect I would venture to say that we delude ourselves if 
we think we can reach a molecular understanding of this 
still enigmatic disease without an opportunity to explore 
cellular and molecular changes in aﬀ  ected human brains. 
Furthermore, it is essential to study at autopsy the brains 
of people who have participated in clinical trials, since 
this is the way to gain clarity over whether the treatment 
manages to abolish the pathology. Examination of a 
meagre eight cases treated with the initial anti-β-amyloid 
vaccine showed clearly that, while the amyloid plaques 
were reduced in most of the cases, the neuroﬁ  brillary 
tangles remained in place [7]. Tangles, as has long been 
known, are the pathological feature that best correlates 
with how demented is a patient with AD [8,9].
Looking to the future, there may be less need to have 
recourse to the practised eye of neuropathologists 
experienced in diagnosing causes of dementia. Use of 
western blotting on fresh-frozen brain homogenates 
oﬀ   ers another way to examine pathological brain 
changes, although this method is not yet in routine use 
for this purpose except in the case of prion diseases [10]. 
I accept that there may come a time when conventional 
neuropathology no longer has a part to play in helping to 
diagnose and understand AD, but that time has not yet 
come and, in my opinion, is likely to be a good way oﬀ  . 
Autopsy examination of well-studied cases of AD and 
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